IP Library Granted Patent US 12698308
Granted Patent B2
US 12698308 · App. 18/554,481 · Granted Aug 4, 2026

Peptide for preventing or treating inflammatory diseases

Inventor: Seong Hyang Sohn (Suwon-si, KR)
Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
C07K14/001A23L33/18A61K47/56A61P37/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12698308
App. No.
18/554,481
Granted
Aug 4, 2026
Kind
B2
Abstract

The present invention relates to: a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 4 to 7 or a fragment thereof; and a pharmaceutical composition for the treatment or prevention of inflammatory diseases or autoimmune diseases, comprising same. The peptide has been confirmed to have an excellent effect of inhibiting cytokines such as IL-17 and TNF alpha, and thus can be provided as a therapeutic agent for various inflammatory diseases, including Behcet's disease.

Claims (13)

1 . A peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, and 7.

2 . The peptide of claim 1 , wherein the N- or C-terminus comprises a palmitoyl group, a hexanoyl group, a myristoyl group, a stearoyl group, an acetyl group, a maleimidobutyryl group, or a PEG.

3 . A conjugate comprising the peptide according to claim 1 conjugated to a biocompatible polymer or fatty acid.

4 . The conjugate of claim 3 , wherein the biocompatible polymer is one or two or more selected from the group consisting of pullulan, chondroitin sulfate, hyaluronic acid (HA), glycol chitosan, starch, chitosan, dextran, pectin, curdlan, poly-L-lysine, poly-aspartic acid (PAA), polylactic acid (PLA), polyglycolide (PGA), poly(ε-caprolactone) (PCL), poly(caprolactone-lactide) random copolymer (PCLA), poly(caprolactone-glycolide) random copolymer (PCGA), poly(lactide-glycolide) random copolymer (PCGA), polyethylene glycol (PEG), pluronic F-68, and pluronic F-127.

5 . The conjugate of claim 3 , wherein the fatty acid is one or two or more selected from the group consisting of hexanoic acid, caprylic acid, capric acid, maleimidobutyric acid, lauric acid, myristic acid, palmitic acid, stearic acid, and cholesterol.

6 . A pharmaceutical composition for treating or preventing an inflammatory disease or autoimmune disease, comprising one or more peptide(s) selected from the group consisting of the peptide(s) according to claim 1 .

7 . The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is any one selected from the group consisting of an oral agent, external agent, suppository, and injection agent.

8 . A cosmetic composition for preventing or alleviating an inflammatory disease or autoimmune disease, comprising one or more peptide(s) selected from the group consisting of the peptide(s) according to claim 1 .

9 . The cosmetic composition of claim 8 , wherein the cosmetic composition has a formulation of a softening toner, nourishing toner, nourishing cream, gel, essence, soap, ointment, balm, or pack.

10 . A health functional food composition for preventing or alleviating an inflammatory disease or autoimmune disease, comprising one or more peptide(s) selected from the group consisting of the peptide(s) according to claim 1 .

11 . A pharmaceutical composition for treating or preventing an inflammatory disease or autoimmune disease, comprising one or more conjugate(s) selected from the group consisting of the conjugates(s) according to claim 3 as an active ingredient.

12 . A cosmetic composition for preventing or alleviating an inflammatory disease or autoimmune disease, comprising one or more conjugate(s) selected from the group consisting of the conjugate(s) according to claim 3 as an active ingredient.

13 . A health functional food composition for preventing or alleviating an inflammatory disease or autoimmune disease, comprising one or more conjugate(s) selected from the group consisting of the conjugate(s) according to claim 3 as an active ingredient.